Erythropoiesis-stimulating agents and heart failure

Area of Science:

• Cardiology
• Nephrology
• Hematology

Background:

• Anemia is a frequent comorbidity in heart failure (HF) patients, associated with worse prognosis.
• The pathophysiology often involves inadequate erythropoietin (EPO) production or bone marrow resistance to EPO.
• This suggests EPO-based therapies could be beneficial for anemic HF patients.

Purpose of the Study:

• To evaluate the potential benefits and safety of erythropoiesis-stimulating agents (ESAs) for treating anemia in heart failure (HF) patients.
• To explore the nonhematopoietic effects of ESAs in the cardiac context.
• To determine the need for large-scale trials investigating ESAs in HF.

Main Methods:

• Review of smaller clinical studies on ESAs in anemic HF patients.
• Consideration of results from two larger, phase II studies.
• Analysis of safety concerns from chronic kidney disease (CKD) patient studies.
• Examination of distinct HF patient characteristics compared to CKD patients.

Main Results:

• Smaller studies indicated ESAs improved surrogate endpoints like left ventricular function and exercise capacity.
• Larger phase II studies did not fully corroborate these promising findings.
• Safety concerns regarding ESAs have emerged from CKD studies.
• ESAs may possess nonhematopoietic cardiac benefits, including anti-apoptotic and pro-angiogenic effects.

Conclusions:

• While smaller studies showed promise, larger trials are needed to confirm ESA efficacy in HF.
• The safety profile of ESAs in HF patients requires further investigation, considering differences from CKD populations.
• Large-scale trials are essential to definitively assess the effect and safety of anemia treatment with ESAs in HF.